for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Knight Therapeutics Inc

GUD.TO

Latest Trade

5.26CAD

Change

-0.04(-0.75%)

Volume

363,622

Today's Range

5.26

 - 

5.35

52 Week Range

4.88

 - 

8.08

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.30
Open
5.30
Volume
363,622
3M AVG Volume
7.63
Today's High
5.35
Today's Low
5.26
52 Week High
8.08
52 Week Low
4.88
Shares Out (MIL)
126.50
Market Cap (MIL)
665.41
Forward P/E
-141.78
Dividend (Yield %)
--

Next Event

Q1 2021 Knight Therapeutics Inc Earnings Release

Latest Developments

More

Knight Therapeutics Reports Fourth Quarter And Year End 2020 Results

Knight Announces Filing Of Preliminary Base Shelf Prospectus

Knight Therapeutics Reports Third Quarter 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Knight Therapeutics Inc

Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.

Industry

Biotechnology & Drugs

Contact Info

3400 De Maisonneuve Blvd W

MONTREAL, QC

H3Z 3B8

Canada

+1.514.4844483

https://www.gud-knight.com/

Executive Leadership

James C. Gale

Independent Chairman of the Board

Samira Sakhia

President, Director

Jonathan Ross Goodman

Chief Executive Officer, Director

Arvind Utchanah

Chief Financial Officer

Amal Khouri

Vice President - Business Development

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2018

0.0K

2019

0.0K

2020

0.2K

2021(E)

0.2K
EPS (CAD)

2018

0.170

2019

0.100

2020

0.320

2021(E)

-0.037
Price To Earnings (TTM)
16.36
Price To Sales (TTM)
3.34
Price To Book (MRQ)
0.77
Price To Cash Flow (TTM)
10.42
Total Debt To Equity (MRQ)
6.34
LT Debt To Equity (MRQ)
0.29
Return on Investment (TTM)
3.58
Return on Equity (TTM)
2.71

Latest News

Latest News

BRIEF-Knight Announces Normal Course Issuer Bid

* KNIGHT THERAPEUTICS - PROPOSES TO PURCHASE, FROM TIME TO TIME OVER NEXT 12 MONTHS, IF CONSIDERED ADVISABLE, UP TO 10.9 MILLION COMMON SHARES OF CO Source text for Eikon: Further company coverage:

BRIEF-Knight Therapeutics Inc - QTRLY Basic Net Loss Per Share $0.01

* KNIGHT THERAPEUTICS INC - QTRLY BASIC NET LOSS PER SHARE $0.01 Source text for Eikon: Further company coverage:

BRIEF-Knight Announces The Re-Launch Of Trelstar® In Canada

* KNIGHT ANNOUNCES THE RE-LAUNCH OF TRELSTAR® IN CANADA Source text for Eikon: Further company coverage:

BRIEF-Knight Therapeutics Announces Approval Of Ibsrela™ In Canada

* KNIGHT THERAPEUTICS ANNOUNCES APPROVAL OF IBSRELA™ IN CANADA

BRIEF-Knight Therapeutics Inc. Announces Triumvira Loan Repayment

* KNIGHT THERAPEUTICS INC. ANNOUNCES TRIUMVIRA LOAN REPAYMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Knight Therapeutics Reports Q4 Loss Per Share Of $0.049

* KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS

Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29-filing

Canada's Knight Therapeutics Inc and shareholders of Biotoscana Investments expect to conclude transfer of control of the Latin American pharmaceutical company by Nov. 29, the latter said in a securities filing on Monday.

Knight Therapeutics to purchase Biotoscana in $281 million deal

Knight Therapeutics <GUD.TO> will buy Brazilian pharmaceutical company Biotoscana Investments <GBIO33.SA> in a deal valued at 1.16 billion reais ($281 million) that will create a pharmaceutical platform in fast growing markets in Latin America.

Shares in Biotoscana, Knight Therapeutics up after deal announcement

Shares in Canada's Knight Therapeutics were up 9% in Toronto after the announcement of acquisition of Latin American pharmaceutical company Biotoscana Investments earlier on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up